Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Cancer Biology & Therapy|October 16, 2009
Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinicallyLiam Morgan, Julia Gee, Sara Pumford, et al.European Journal of Cancer (Oxford, England : 1990)|June 10, 2008
Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significanceHany Onsy Habashy, Desmond G Powe, Emad A Rakha, et al.BMC Cancer|October 9, 2012
Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronanStephen Hiscox, Bedanta Baruha, Chris Smith, et al.Breast Cancer Research : BCR|March 29, 2008
Evaluation of the current knowledge limitations in breast cancer research: a gap analysisAlastair Thompson, Keith Brennan, Angela Cox, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibitionJoan Albanell, Federico Rojo, Steve Averbuch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotypeEmad A Rakha, Maysa E El-Sayed, Andrew R Green, et al.BJC Reports|November 8, 2024
Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trialMark Beresford, Angela Casbard, Zoe Hudson, et al.European Journal of Cancer (Oxford, England : 1990)|November 24, 2007
Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomesEmad A Rakha, Maysa E El-Sayed, Desmond G Powe, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2018
Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIPLuke Piggott, Andreia Silva, Timothy Robinson, et al.Plos One|March 28, 2014
Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targetsDavid Britton, Yoh Zen, Alberto Quaglia, et al.Pageof 3